Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer

<p>Abstract</p> <p>Background</p> <p>Interleukin-12 (IL-12) is well characterized to induce cellular antitumoral immunity by activation of NK-cells and T-lymphocytes. However, systemic administration of recombinant human IL-12 resulted in severe toxicity without percept...

Full description

Bibliographic Details
Main Authors: Schäfer Hansjörg, Thaiss Friedrich, Stahmer Ingrid, Krüger Karen, Krieger Thorsten, Wulff Holger, Block Andreas
Format: Article
Language:English
Published: BMC 2007-06-01
Series:BMC Biotechnology
Online Access:http://www.biomedcentral.com/1472-6750/7/35
id doaj-fbc91cc2586c441bbc3a7d5a81c1bdf3
record_format Article
spelling doaj-fbc91cc2586c441bbc3a7d5a81c1bdf32020-11-25T03:48:50ZengBMCBMC Biotechnology1472-67502007-06-01713510.1186/1472-6750-7-35Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancerSchäfer HansjörgThaiss FriedrichStahmer IngridKrüger KarenKrieger ThorstenWulff HolgerBlock Andreas<p>Abstract</p> <p>Background</p> <p>Interleukin-12 (IL-12) is well characterized to induce cellular antitumoral immunity by activation of NK-cells and T-lymphocytes. However, systemic administration of recombinant human IL-12 resulted in severe toxicity without perceptible therapeutic benefit. Even though intratumoral expression of IL-12 leads to tumor regression and long-term survival in a variety of animal models, clinical trials have not yet shown a significant therapeutic benefit. One major obstacle in the treatment with IL-12 is to overcome the relatively low expression of the therapeutic gene without compromising the safety of such an approach. Our objective was to generate an adenoviral vector system enabling the regulated expression of very high levels of bioactive, human IL-12.</p> <p>Results</p> <p>High gene expression was obtained utilizing the VP16 herpes simplex transactivator. Strong regulation of gene expression was realized by fusion of the VP16 to a tetracycline repressor with binding of the fusion protein to a flanking tetracycline operator and further enhanced by auto-regulated expression of its fusion gene within a bicistronic promoter construct. Infection of human colon cancer cells (HT29) at a multiplicity of infection (m.o.i.) of 10 resulted in the production of up to 8000 ng/10<sup>6 </sup>cells in 48 h, thus exceeding any published vector system so far. Doxycycline concentrations as low as 30 ng/ml resulted in up to 5000-fold suppression, enabling significant reduction of gene expression in a possible clinical setting. Bioactivity of the human single-chain IL-12 was similar to purified human heterodimeric IL-12. Frozen sections of human colon cancer showed high expression of the coxsackie adenovirus receptor with significant production of human single chain IL-12 in colon cancer biopsies after infection with 3*10<sup>7 </sup>p.f.u. Ad.3r-scIL12. Doxycycline mediated suppression of gene expression was up to 9000-fold in the infected colon cancer tissue.</p> <p>Conclusion</p> <p>VP16 transactivator-mediated and doxycycline-regulated expression of the human interleukin-12 gene enables highly efficient and tightly controlled cytokine expression in human cancer. These data illustrate the potential of the described adenoviral vector system for the safe and superior expression of therapeutic genes in the treatment of colorectal cancer and other malignancies.</p> http://www.biomedcentral.com/1472-6750/7/35
collection DOAJ
language English
format Article
sources DOAJ
author Schäfer Hansjörg
Thaiss Friedrich
Stahmer Ingrid
Krüger Karen
Krieger Thorsten
Wulff Holger
Block Andreas
spellingShingle Schäfer Hansjörg
Thaiss Friedrich
Stahmer Ingrid
Krüger Karen
Krieger Thorsten
Wulff Holger
Block Andreas
Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer
BMC Biotechnology
author_facet Schäfer Hansjörg
Thaiss Friedrich
Stahmer Ingrid
Krüger Karen
Krieger Thorsten
Wulff Holger
Block Andreas
author_sort Schäfer Hansjörg
title Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer
title_short Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer
title_full Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer
title_fullStr Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer
title_full_unstemmed Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer
title_sort cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer
publisher BMC
series BMC Biotechnology
issn 1472-6750
publishDate 2007-06-01
description <p>Abstract</p> <p>Background</p> <p>Interleukin-12 (IL-12) is well characterized to induce cellular antitumoral immunity by activation of NK-cells and T-lymphocytes. However, systemic administration of recombinant human IL-12 resulted in severe toxicity without perceptible therapeutic benefit. Even though intratumoral expression of IL-12 leads to tumor regression and long-term survival in a variety of animal models, clinical trials have not yet shown a significant therapeutic benefit. One major obstacle in the treatment with IL-12 is to overcome the relatively low expression of the therapeutic gene without compromising the safety of such an approach. Our objective was to generate an adenoviral vector system enabling the regulated expression of very high levels of bioactive, human IL-12.</p> <p>Results</p> <p>High gene expression was obtained utilizing the VP16 herpes simplex transactivator. Strong regulation of gene expression was realized by fusion of the VP16 to a tetracycline repressor with binding of the fusion protein to a flanking tetracycline operator and further enhanced by auto-regulated expression of its fusion gene within a bicistronic promoter construct. Infection of human colon cancer cells (HT29) at a multiplicity of infection (m.o.i.) of 10 resulted in the production of up to 8000 ng/10<sup>6 </sup>cells in 48 h, thus exceeding any published vector system so far. Doxycycline concentrations as low as 30 ng/ml resulted in up to 5000-fold suppression, enabling significant reduction of gene expression in a possible clinical setting. Bioactivity of the human single-chain IL-12 was similar to purified human heterodimeric IL-12. Frozen sections of human colon cancer showed high expression of the coxsackie adenovirus receptor with significant production of human single chain IL-12 in colon cancer biopsies after infection with 3*10<sup>7 </sup>p.f.u. Ad.3r-scIL12. Doxycycline mediated suppression of gene expression was up to 9000-fold in the infected colon cancer tissue.</p> <p>Conclusion</p> <p>VP16 transactivator-mediated and doxycycline-regulated expression of the human interleukin-12 gene enables highly efficient and tightly controlled cytokine expression in human cancer. These data illustrate the potential of the described adenoviral vector system for the safe and superior expression of therapeutic genes in the treatment of colorectal cancer and other malignancies.</p>
url http://www.biomedcentral.com/1472-6750/7/35
work_keys_str_mv AT schaferhansjorg cloningandcharacterizationofanadenoviralvectorforhighlyefficientanddoxycyclinesuppressibleexpressionofbioactivehumansinglechaininterleukin12incoloncancer
AT thaissfriedrich cloningandcharacterizationofanadenoviralvectorforhighlyefficientanddoxycyclinesuppressibleexpressionofbioactivehumansinglechaininterleukin12incoloncancer
AT stahmeringrid cloningandcharacterizationofanadenoviralvectorforhighlyefficientanddoxycyclinesuppressibleexpressionofbioactivehumansinglechaininterleukin12incoloncancer
AT krugerkaren cloningandcharacterizationofanadenoviralvectorforhighlyefficientanddoxycyclinesuppressibleexpressionofbioactivehumansinglechaininterleukin12incoloncancer
AT kriegerthorsten cloningandcharacterizationofanadenoviralvectorforhighlyefficientanddoxycyclinesuppressibleexpressionofbioactivehumansinglechaininterleukin12incoloncancer
AT wulffholger cloningandcharacterizationofanadenoviralvectorforhighlyefficientanddoxycyclinesuppressibleexpressionofbioactivehumansinglechaininterleukin12incoloncancer
AT blockandreas cloningandcharacterizationofanadenoviralvectorforhighlyefficientanddoxycyclinesuppressibleexpressionofbioactivehumansinglechaininterleukin12incoloncancer
_version_ 1724496819640074240